{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T08:55:02Z","timestamp":1709715302962},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.remn.2017.10.008","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T13:35:59Z","timestamp":1518528959000},"page":"103-109","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u00bfConstituir\u00e1n en el futuro los radioligandos de 68 Ga-PSMA la \u00fanica elecci\u00f3n de la Medicina Nuclear para el c\u00e1ncer de pr\u00f3stata? Actualizaci\u00f3n cl\u00ednica"],"prefix":"10.1016","volume":"37","author":[{"given":"V.","family":"Cuccurullo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.D.","family":"di Stasio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ciarmiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remn.2017.10.008_bib0155","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.7314\/APJCP.2015.16.13.5137","article-title":"Epidemiology of prostate cancer","volume":"16","author":"Bashir","year":"2015","journal-title":"Asian Pac J Cancer Prev."},{"key":"10.1016\/j.remn.2017.10.008_bib0160","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4111\/icu.2016.57.1.14","article-title":"Current status of active surveillance in prostate cancer","volume":"57","author":"Chung","year":"2016","journal-title":"Investig Clin Urol."},{"key":"10.1016\/j.remn.2017.10.008_bib0165","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1148\/rg.2017170035","article-title":"Clinical PET imaging in prostate cancer","volume":"37","author":"Wallitt","year":"2017","journal-title":"Radiographics."},{"key":"10.1016\/j.remn.2017.10.008_bib0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eururo.2017.02.006","article-title":"Prostate cancer and the John West effect","volume":"72","year":"2017","journal-title":"Eur Urol."},{"key":"10.1016\/j.remn.2017.10.008_bib0175","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2967\/jnumed.114.142679","article-title":"Is radiocholine PET\/CT already clinically useful in patients with prostate cancer?","volume":"55","author":"Mansi","year":"2014","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remn.2017.10.008_bib0180","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0","volume":"44","author":"Fendler","year":"2017","journal-title":"Eur J Nucl Med Mol Imag."},{"key":"10.1016\/j.remn.2017.10.008_bib0185","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","article-title":"Prostate cancer","volume":"387","author":"Attard","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.remn.2017.10.008_bib0190","first-page":"CD004720","article-title":"Screening for prostate cancer","volume":"1","author":"Ilic","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.remn.2017.10.008_bib0195","first-page":"ED000067","article-title":"Screening for prostate cancer: Shaping the debate on benefits and harms","volume":"9","author":"Dahm","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.remn.2017.10.008_bib0200","doi-asserted-by":"crossref","first-page":"376","DOI":"10.21037\/tau.2017.01.06","article-title":"Multiparametric magnetic resonance imaging of the prostate \u2014 a basic tutorial","volume":"6","author":"Cabarrus","year":"2017","journal-title":"Transl Androl Urol."},{"key":"10.1016\/j.remn.2017.10.008_bib0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1874471011306010007","article-title":"Bone metastases radiopharmaceuticals: An overview","volume":"6","author":"Cuccurullo","year":"2013","journal-title":"Curr Radiopharm."},{"key":"10.1016\/j.remn.2017.10.008_bib0210","first-page":"353","article-title":"Pathophysiological premises to radiotracers for bone metastases","volume":"55","author":"Cuccurullo","year":"2011","journal-title":"Q J Nucl Med Mol Imag."},{"key":"10.1016\/j.remn.2017.10.008_bib0215","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/MNM.0000000000000582","article-title":"Radiolabeled choline PET\/CT before salvage lymphadenectomy dissection: A systematic review and meta-analysis","volume":"37","author":"Evangelista","year":"2016","journal-title":"Nucl Med Commun."},{"key":"10.1016\/j.remn.2017.10.008_bib0220","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/j.semnuclmed.2016.07.005","article-title":"PET tracers beyond FDG in prostate cancer","volume":"46","author":"Schuster","year":"2016","journal-title":"Semin Nucl Med."},{"key":"10.1016\/j.remn.2017.10.008_bib0225","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/1871520616666160926115008","article-title":"Targeted therapy towards cancer \u2014 a perspective","volume":"17","author":"Kitson","year":"2017","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.remn.2017.10.008_bib0230","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40644-015-0038-0","article-title":"FDG-PET\/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy","volume":"15","author":"Beauregard","year":"2015","journal-title":"Cancer Imag."},{"key":"10.1016\/j.remn.2017.10.008_bib0235","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jcp.25478","article-title":"Biochemical and pathophysiological premises to positron emission tomography with choline radiotracers","volume":"232","author":"Cuccurullo","year":"2017","journal-title":"J Cell Physiol."},{"key":"10.1016\/j.remn.2017.10.008_bib0240","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.nucmedbio.2014.12.019","article-title":"18F-fluoromethylcholine or 18F-fluoroethylcholine pet for prostate cancer imaging: Which is better? A literature revision","volume":"42","author":"Evangelista","year":"2015","journal-title":"Nucl Med Biol."},{"key":"10.1016\/j.remn.2017.10.008_bib0245","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eururo.2016.01.029","article-title":"New clinical indications for (18)F\/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: A systematic review of the literature","volume":"70","author":"Evangelista","year":"2016","journal-title":"Eur Urol."},{"key":"10.1016\/j.remn.2017.10.008_bib0250","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12149-016-1078-7","article-title":"Acquisition with (11)C-choline and (18)F-fluorocholine PET\/CT for patients with biochemical recurrence of prostate cancer: A systematic review and meta-analysis","volume":"30","author":"Von Eyben","year":"2016","journal-title":"Ann Nucl Med."},{"key":"10.1016\/j.remn.2017.10.008_bib0255","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","article-title":"PSMA ligands for PET-imaging of prostate cancer","volume":"58","author":"Schwarzenb\u00f6ck","year":"2017","journal-title":"J Nucl Med."},{"issue":"Suppl. 2","key":"10.1016\/j.remn.2017.10.008_bib0260","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","article-title":"Prostate-specific membrane antigen ligands for imaging and therapy","volume":"58","author":"Eiber","year":"2017","journal-title":"J Nucl Med."},{"key":"10.1016\/j.remn.2017.10.008_bib0265","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imag."},{"key":"10.1016\/j.remn.2017.10.008_bib0270","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients","volume":"44","author":"Afshar-Oromieh","year":"2017","journal-title":"Eur J Nucl Med Mol Imag."},{"key":"10.1016\/j.remn.2017.10.008_bib0275","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.euf.2016.02.006","article-title":"Imaging for prostate cancer recurrence","volume":"2","author":"Maurer","year":"2016","journal-title":"Eur Urol Focus."},{"key":"10.1016\/j.remn.2017.10.008_bib0280","doi-asserted-by":"crossref","first-page":"55567","DOI":"10.18632\/oncotarget.15698","article-title":"Radioligand therapy of metastatic prostate cancer using 177\/Lu-PSMA-617 after radiation exposure to 223\/Ra-dichloride","volume":"8","author":"Ahmadzadehfar","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.remn.2017.10.008_bib0285","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nucmedbio.2017.04.001","article-title":"Clinical results and economic considerations of 68Ga-PSMA and radiolabeled choline in prostate cancer","volume":"50","author":"Evangelista","year":"2017","journal-title":"Nucl Med Biol."},{"key":"10.1016\/j.remn.2017.10.008_bib0290","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.urology.2017.04.019","article-title":"Diagnostic accuracy of 64Copper prostate-specific membrane antigen positron emission tomography\/computed tomography for primary lymph node staging of intermediate- to high-risk prostate cancer: Our preliminary experience","volume":"106","author":"Cantiello","year":"2017","journal-title":"Urology."},{"key":"10.1016\/j.remn.2017.10.008_bib0295","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-015-3189-0","article-title":"Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: From (223)Ra-dichloride to new horizons for therapeutic response assessment","volume":"43","author":"Bombardieri","year":"2016","journal-title":"Eur J Nucl Med Mol Imag."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X17302366?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X17302366?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T23:28:47Z","timestamp":1535066927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253654X17302366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S2253654X17302366"],"URL":"https:\/\/doi.org\/10.1016\/j.remn.2017.10.008","relation":{},"ISSN":["2253-654X"],"issn-type":[{"value":"2253-654X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00bfConstituir\u00e1n en el futuro los radioligandos de 68Ga-PSMA la \u00fanica elecci\u00f3n de la Medicina Nuclear para el c\u00e1ncer de pr\u00f3stata? Actualizaci\u00f3n cl\u00ednica","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2017.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U. y SEMNIM. All rights reserved.","name":"copyright","label":"Copyright"}]}}